Crizotinib and entrectinib are being compared head-to-head in patients with ROS1-positive non small cell lung cancer, including those who have brain metastases, in a phase III randomized controlled trial (NCT04603807) that has been accepting patients since 2021 [55]. The gene discussed is ROS1; the disease is non-small cell lung carcinoma.